Cancer Support Community launches national program to assist patients with cancer

AmgenThe Cancer Support Community (CSC) and the Amgen Foundation, today announced the launch of Open to Options", a program designed to bridge the communications gap between physicians and patients and inspire patient confidence in making treatment decisions. Following a successful pilot funded by the Centers for Disease Control (CDC), the Open to Options program is ready to provide professional counselors who help more people formulate a list of personalized questions and concerns to be taken into the oncologist's office.

"The number and complexity of options for treating cancer can be overwhelming for people," said Vicki Kennedy, Vice President of Program Development & Delivery at the CSC. "The goal of Open to Options is to help people affected by all cancers evaluate their options so they can feel more confident and communicate clearly with their doctor so a decision is made that best fits their individual desires and goals."

"We are delighted to support the Open to Options program as part of our ongoing commitment to empowering patients to take an active role in their care," said Jean Lim Terra, president of the Amgen Foundation. "The resources that the Cancer Support Community provides individuals and families helps to ensure that those affected by cancer have the knowledge and support they need to make the right decisions at the right time."

The program was created in response to CSC research that found the majority of cancer patients are unprepared to make treatment decisions. A CSC pilot study funded by the Centers for Disease Control and Prevention found that 9 out of 10 patients felt that the list of questions, concerns and expectations contributed to a more productive appointment with their doctor and that the oncologist answered most of their questions. The study also showed:

  • A decrease in anxiety about the appointment for most patients
  • Repeat use of the tools and techniques learned
  • Patient and physician satisfaction

"Open to Options helped me prioritize my questions and concerns in a concise, logical order to help me optimize my time with the oncologist," said Trish H., a multiple myeloma patient who participated in the Open to Options pilot. "When I went into his office, I had my concerns printed out and when I left the appointment I knew that I had decided on the treatment option that was right for me."

About the Cancer Support Community
Backed by evidence that the best cancer care includes emotional and social support, the Cancer Support Community offers these services to all people affected by cancer. Likely the largest professionally-led network of cancer support worldwide, the organization delivers a comprehensive menu of personalized and essential services. Because no cancer care plan is complete without emotional and social support, the Cancer Support Community has a vibrant network of community-based centers and online services run by trained and licensed professionals.

In July 2009, The Wellness Community and Gilda's Club Worldwide joined forces to become the Cancer Support Community. The combined organization provides high-quality psychological and social support through a network of nearly 50 local affiliates, more than 100 satellite locations and online.

About the Amgen Foundation
The Amgen Foundation seeks to advance science education; improve patient access to quality care; and strengthen the communities where Amgen staff members live and work. Since 1991, the Foundation has made nearly $180 million in grants to nonprofit organizations throughout the United States, Puerto Rico and Europe that impact society in inspiring and innovative ways, and those that provide disaster relief efforts both domestically and internationally.

Most Popular Now

Top 20 World Pharma News of 2016

Look back at the most prominent moments from the year 2016. We are proud to announce the 20 most popular World Pharma News from 2016, the most commonly viewed news accord...

Read more

New precision medicine tool helps optimize cancer …

Columbia University Medical Center (CUMC) researchers have created a computational tool that can rapidly predict which genes are implicated in an individual's cancer and ...

Read more

Roche's emicizumab for haemophilia A meets primary…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the primary endpoint has been met for the phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 y...

Read more

Sanofi and Boehringer Ingelheim confirm Closing of…

Sanofi and Boehringer Ingelheim confirmed that the strategic transaction signed in June 2016, which consists of an exchange of Sanofi's animal health business (Merial) an...

Read more

Diabetes, heart disease, and back pain dominate US…

Just 20 conditions make up more than half of all spending on health care in the United States, according to a new comprehensive financial analysis that examines spending ...

Read more

FDA approves first drug for spinal muscular atroph…

The U.S. Food and Drug Administration has approved Spinraza (nusinersen), the first drug approved to treat children and adults with spinal muscular atrophy (SMA), a rare ...

Read more

Novartis invests in next generation therapies to r…

Novartis announced today a collaboration and option agreement with Ionis Pharmaceuticals, Inc. and its affiliate Akcea Therapeutics, Inc., to license two novel treatments...

Read more

Topical treatment activates immune system to clear…

A combination of two FDA-approved drugs - a topical chemotherapy and an immune-system-activating compound - was able to rapidly clear actinic keratosis lesions from patie...

Read more

Vaccine shows promising results for early-stage br…

Deregulation and inhibition of the immune system contributes to cancer development. Many therapeutic strategies aim to re-stimulate the immune system to recognize cancer ...

Read more

Bristol-Myers Squibb announces immunotherapy clini…

Bristol-Myers Squibb Company (NYSE:BMY) today announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate the combination of Bristol-Myers Squi...

Read more

Anti-aging therapies targeting senescent cells: Fa…

It's an exciting time to be an elderly mouse. Researchers believe that by removing senescent cells (cells with a persistent damage response), which naturally accumulate w...

Read more

Novo Nordisk and Glooko partner to develop digital…

Novo Nordisk and Glooko today announced that the two companies will work together to deliver jointly-developed and branded digital health solutions for people with diabet...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]